Bladder Cancer, 2015 Background: Bacillus Calmette-Guerin (BCG) is the most effective intravesical therapy for non-muscle invasive bladder cancer (NMIBC), but patients can fail or supply shortages can develop. For BCG failures, radical cystectomy is recommended.
Ryan L. Steinberg +3 more
doaj +1 more source
'I've used the word cancer but it's actually good news' : discursive performativity of cancer and the identity of urological cancer services [PDF]
, 2015 © 2015 Foundation for the Sociology of Health & Illness. Acknowledgements We are grateful to the patients and staff who took part in the study, and to two anonymous reviewers whose thoughtful comments helped refine our thinking.
Kazimierczak, Karolina Agata +1 more
core +1 more source
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Molecular Oncology, EarlyView.The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu +18 more
wiley +1 more source
Bladder Cancer, 2017 Robot-assisted radical cystectomy (RARC) has seen remarkable growth in the last decade. Despite a low level of evidence, numerous publications reporting on outcomes after RARC are now available. While definitive data on the long-term oncologic safety and
François Audenet, John P. Sfakianos
doaj +1 more source
Genetic variation in Glutathione S-Transferase Omega-1, Arsenic Methyltransferase and Methylene-tetrahydrofolate Reductase, arsenic exposure and bladder cancer: a case–control study [PDF]
, 2012 Background Ingestion of groundwater with high concentrations of inorganic arsenic has been linked to adverse health outcomes, including bladder cancer, however studies have not consistently observed any elevation in risk at lower concentrations.
Beebe-Dimmer, Jennifer L +10 more
core +3 more sources
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Molecular Correlates of Responses to Dacomitinib and Afatinib in Bladder Cancer
Bladder Cancer, 2018 Background: The HER family of proteins (EGFR, HER2, HER3 and HER4) have long been thought to be therapeutic targets for bladder cancer, but previous clinical trials targeting these proteins have been disappointing.
Shuzo Tamura +15 more
doaj +1 more source
Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). [PDF]
, 2019 BackgroundThe aim of this study was to evaluate the efficacy and safety of chemoradiotherapy (RCT) combined with regional deep hyperthermia (RHT) of high-risk bladder cancer after transurethral resection of bladder tumor (TUR-BT).Materials and ...
Bertz, Simone +12 more
core
Clinical proteomics for precision medicine: the bladder cancer case [PDF]
, 2017 Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of –omics based approaches.
Frantzi, Maria +4 more
core +1 more source
A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence [PDF]
, 2023 Hong‐Wei An +14 more
openalex +1 more source